Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer
| Autor: | Francesco Schettini, Sergio Venturini, Mario Giuliano, Matteo Lambertini, David J. Pinato, Concetta Elisa Onesti, Pietro De Placido, Nadia Harbeck, Diana Lüftner, Hannelore Denys, Peter Van Dam, Grazia Arpino, Khalil Zaman, Giorgio Mustacchi, Joseph Gligorov, Ahmad Awada, Mario Campone, Hans Wildiers, Alessandra Gennari, Vivianne Tjan-Heijnen, Rupert Bartsch, Javier Cortes, Ida Paris, Miguel Martín, Sabino De Placido, Lucia Del Mastro, Guy Jerusalem, Giuseppe Curigliano, Aleix Prat, Daniele Generali |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [Schettini F] Translational Genomics and Targeted Therapies in Solid Tumors, Barcelona, Spain. Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain. Department of Medicine, University of Barcelona, Barcelona, Spain. [Venturini S] Department of Economic and Social Sciences, Catholic University of Sacred Heart - Cremona Campus, Cremona, Italy. [Giuliano M] Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. [Lambertini M] Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy. Department of Medical Oncology, U.O.C Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy. [Pinato DJ] Division of Cancer, Department of Surgery and Cancer, Imperial College London, SW7 2AZ London, UK. Department of Translational Medicine, Università del Piemonte Orientale 'A. Avogadro', Novara, Italy. [Onesti CE] Clinical and Oncological Research Department, IRCCS Regina Elena National Cancer Institute, Rome, Italy. [Cortes J] International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain. Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus, Schettini, Francesco, Venturini, Sergio, Giuliano, Mario, Lambertini, Matteo, Pinato, David J, Onesti, Concetta Elisa, De Placido, Pietro, Harbeck, Nadia, Lüftner, Diana, Denys, Hannelore, Van Dam, Peter, Arpino, Grazia, Zaman, Khalil, Mustacchi, Giorgio, Gligorov, Joseph, Awada, Ahmad, Campone, Mario, Wildiers, Han, Gennari, Alessandra, Tjan-Heijnen, Vivianne, Bartsch, Rupert, Cortes, Javier, Paris, Ida, Martín, Miguel, De Placido, Sabino, Del Mastro, Lucia, Jerusalem, Guy, Curigliano, Giuseppe, Prat, Aleix, Generali, Daniele |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
PD-L1
Paclitaxel Network Meta-Analysis BRCA Immunoteràpia Medicaments antineoplàstics - Ús terapèutic Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] Algorismes Triple Negative Breast Neoplasms Immunotheraphy Poly(ADP-ribose) Polymerase Inhibitors Other subheadings::Other subheadings::/drug therapy [Other subheadings] B7-H1 Antigen Sacituzumab govitecan Càncer de mama Metastasis Breast cancer Metàstasi Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT] Antineoplastic Combined Chemotherapy Protocols Medicine and Health Sciences Humans Radiology Nuclear Medicine and imaging Trastuzumab deruxtecan Triple negative breast cancer PARP inhibitors Bayesian network meta-analysi terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS] Enzyme inhibitors Bayes Theorem General Medicine neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos [ENFERMEDADES] Bayesian statistical decision Bevacizumab PARP inhibitor Estadística bayesiana Inhibidors enzimàtics Oncology Settore SECS-S/01 - STATISTICA Mama - Càncer - Tractament Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms [DISEASES] Bayesian network meta-analysis Therapeutic algorithm Human medicine HER2-low Immunotherapy Pembrolizumab Algorithms |
| Zdroj: | Scientia CANCER TREATMENT REVIEWS Cancer treatment reviews |
| ISSN: | 0305-7372 1532-1967 |
| Popis: | Immunotherapy; PARP inhibitors; Pembrolizumab Immunoteràpia; Inhibidors de PARP; Pembrolizumab Inmunoterapia; Inhibidores de PARP; Pembrolizumab Metastatic triple-negative breast cancer (mTNBC) is a poor prognostic disease with limited treatments and uncertain therapeutic algorithms. We performed a systematic review and multiple Bayesian network meta-analyses according to treatment line to establish an optimal therapeutic sequencing strategy for this lethal disease. We included 125 first-line trials (37,812 patients) and 33 s/further-lines trials (11,321 patients). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rates (ORR), overall survival (OS) and safety, for first and further lines, separately. We also estimated separate treatment rankings for the first and subsequent lines according to each endpoint, based on (surface under the cumulative ranking curve) SUCRA values. No first-line treatment was associated with superior PFS and OS than paclitaxel ± bevacizumab. Platinum-based polychemotherapies were generally superior in terms of ORR, at the cost of higher toxicity.. PARP-inhibitors in germline-BRCA1/2-mutant patients, and immunotherapy + chemotherapy in PD-L1-positive mTNBC, performed similar to paclitaxel ± bevacizumab. In PD-L1-positive mTNBC, pembrolizumab + chemotherapy was better than atezolizumab + nab-paclitaxel in terms of OS according to SUCRA values. In second/further-lines, sacituzumab govitecan outperformed all other treatments on all endpoints, followed by PARP-inhibitors in germline-BRCA1/2-mutant tumors. Trastuzumab deruxtecan in HER2-low mTNBC performed similarly and was the best advanced-line treatment in terms of PFS and OS after sacituzumab govitecan, according to SUCRA values. Moreover, comparisons with sacituzumab govitecan, talazoparib and olaparib were not statistically significant. The most effective alternatives or candidates for subsequent lines were represented by nab-paclitaxel (in ORR), capecitabine (in PFS) and eribulin (in PFS and OS). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect